# Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion

> **NCT02614937** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ohr Pharmaceutical Inc.** · enrollment: 20 (actual)

## Conditions studied

- Retinal Vein Occlusion
- Macular Edema

## Interventions

- **DRUG:** ranibizumab
- **DRUG:** Squalamine Lactate Ophthalmic Solution, 0.2%

## Key facts

- **NCT ID:** NCT02614937
- **Lead sponsor:** Ohr Pharmaceutical Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02614937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02614937, "Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02614937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*